<DOC>
	<DOCNO>NCT00025779</DOCNO>
	<brief_summary>This study evaluate efficacy safety methylphenidate treat hyperactivity , impulsiveness , distractibility 60 child adolescent Pervasive Developmental Disorders ( PDD ) . Methylphenidate ( Ritalin ) approve Food Drug Administration treatment child adolescent Attention Deficit Hyperactivity Disorder ( ADHD ) . Data support safety effectiveness treat ADHD symptom PDD limit . Children adolescents show positive response methylphenidate invite participate pilot study non-stimulant medication guanfacine ( Tenex ) .</brief_summary>
	<brief_title>Methylphenidate Children Adolescents With Pervasive Developmental Disorders</brief_title>
	<detailed_description>The safety efficacy methylphenidate ( MPH ) 60 child adolescent PDD behavioral difficulty ( hyperactivity , impulsiveness distractibility ) evaluate multi-dose , 4-week randomize , crossover , placebo-controlled study . The MPH study three part : Test-Dose Period , Double-Blind trial 8-Week Extension Period ( open-label ) . After screen visit , eligible child start 1-week Test-Dose Period . During week , child give three MPH dos use Double-Blind trial make sure serious side effect . If problem encounter high dose level , dose give Double-Blind phase . The Double-Blind phase last 4 week consist three different MPH dose level week placebo . Each treatment/dose give 1 week , neither researcher participant ' family know whether medication placebo MPH . Children well phase continue best dose MPH ( determine Double-Blind phase ) additional eight week ( open-label ) . Those show significant improvement Double-Blind phase , tolerate MPH Test Dose Period , able take MPH begin study offer open-label treatment guanfacine 8 week . Prior randomization MPH trial OR entry open-label guanfacine trial , medication-free period child currently medication . The withdrawal conduct clinically appropriate way ( depend drug duration treatment ) minimize withdrawal effect . This period establish drug-free baseline measurement minimize drug-drug interaction . No participant withdrawn currently effective medication .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Developmental Disabilities</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Diagnosis PDD ( include Asperger 's Disorder Autistic Disorder ) Clinically significant symptom ADHD Mental age least 18 month Blood pressure within normal range age gender Weight 16 kg Absence chronic tic disorder Absence medical condition would incompatible study treatment Absence evidence hypersensitivity study treatment</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Hyperactivity</keyword>
	<keyword>Distractibility</keyword>
	<keyword>Impulsiveness</keyword>
	<keyword>Pervasive Development Disorders</keyword>
</DOC>